Circulating tumor DNA (ctDNA) consists of short, double-stranded DNA fragments that are released into the circulation by tumor cells. With the advent of newer molecular platforms, ctDNA can be detected with high sensitivity and specificity in plasma. The assay's noninvasive nature, ability to reflect intratumoral heterogeneity, short turnaround time, and ability to obtain serial samples make it an attractive option compared with traditional tissue biopsy tumor sequencing. Currently, this technology is mostly being used for the detection of EGFR mutations in patients with advanced non-small-cell lung cancer where tissue is inadequate to detect EGFR mutations that drive acquired resistance, most notably EGFR T790M. Emerging uses include the incorporation of ctDNA testing into primary diagnosis, treatment monitoring, detection of minimal residual disease, and detection of early-stage disease in screening populations. This review summarizes both validated and evolving uses of ctDNA testing in non-small-cell lung cancer in the context of oncologists' daily practice and some of its potential challenges in the era of targeted therapy and immunotherapy. 1-3 Certain conditions that cause tissue damage, such as myocardial infarction, trauma, and cancer, can result in increased concentrations of cfDNA. 3 The cfDNA derived from tumors, known as circulating tumor DNA (ctDNA), is a product of apoptosis and necrosis and is distinguished from other cfDNA by the presence of somatic mutations representative of tumor biology absent in normal cells. Depending on the size, vascularity, and location of the tumor, the amount of ctDNA can range from , 0.01% to . 90% of all DNA present in the plasma. 4, 5 In patients with advanced non-small-cell lung cancer (NSCLC), ctDNA detection rates that range from 80% to . 95% have been reported with the use of current technology.
INTRODUCTION
Several tissues, including tumors, shed short, double-stranded DNA fragments called cell-free DNA (cfDNA) into the circulation. [1] [2] [3] Certain conditions that cause tissue damage, such as myocardial infarction, trauma, and cancer, can result in increased concentrations of cfDNA. 3 The cfDNA derived from tumors, known as circulating tumor DNA (ctDNA), is a product of apoptosis and necrosis and is distinguished from other cfDNA by the presence of somatic mutations representative of tumor biology absent in normal cells. Depending on the size, vascularity, and location of the tumor, the amount of ctDNA can range from , 0.01% to . 90% of all DNA present in the plasma. 4, 5 In patients with advanced non-small-cell lung cancer (NSCLC), ctDNA detection rates that range from 80% to . 95% have been reported with the use of current technology. 6, 7 TESTING PLATFORMS FOR ctDNA
Although the presence of ctDNA has been known for decades, sequencing techniques that are both sensitive and specific have only recently been established. 8 Older sequencing techniques, such as Sanger and pyrosequencing, often are not sensitive enough to detect very low levels of tumor DNA. 8 The two most common newer methods are digital polymerase chain reaction (PCR)-and next-generation sequencing (NGS)-based assays 8, 9 (Table 1) .
PCR-Based Assays
Allele-specific PCR, such as amplification refractory mutation system (ARMS), is relatively inexpensive and easy to use but limited by its low sensitivity and relatively narrow spectrum of detection of genomic alterations in a given sample. 8 Digital PCR-based methods, such as beads, emulsion, amplification, and magnetics (BEAMing) and droplet digital PCR (ddPCR), allow precise enumeration of the total number of template molecules that carry a mutation of interest and can achieve detection limits to as low as 0.01%. 8 These methods are relatively inexpensive and have high sensitivity and specificity, but they can only interrogate a small number of mutations at a time. Although ddPCR is capable of reliably detecting specific targetable mutations, including EGFR, KRAS, and other known driver mutations, it cannot easily detect copy number alterations and rearrangements (eg, ALK, ROS1). 
NGS-Based Assays
NGS allows for massive parallel sequencing of millions of DNA fragments from a single sample and can detect numerous potential mutations at a time, including single nucleotide variants, insertion or deletion of bases (indels), and gene rearrangements, with high sensitivity and specificity. 6, 8 These approaches can be focused or broad depending on the number of regions that they interrogate. Several commercially available multigene panels that use NGS include key genes that may have therapeutic implications in NSCLC. 5, 7 The broad NGS-based methods include whole-exome sequencing and whole-genome sequencing, which have the advantage of not restricting the sequencing space; however, these methods have not yet been extensively tested for ctDNA. 12 Several commercially available ctDNA testing platforms are listed in Table 2 .
VALIDATED APPLICATIONS
Over the past decade, NSCLC subtyping has evolved from histologic to molecular based. 13 In advanced NSCLC, the detection of activating EGFR mutations, ALK rearrangements, and ROS1 fusions has expanded targeted treatment options with dramatically improved outcomes. 7, 14 In addition, a growing number of promising agents can target other relevant oncogenic driver mutations, such as MET, RET, BRAF, HER2, and NTRK1. 15 ctDNA is a promising noninvasive detection method for relevant mutations, primary diagnosis, treatment monitoring, and resistance mutations. It has the potential to reduce dependence on invasive biopsies, turnaround time for results, and health care costs (Table 3) . We describe several actual patients whose conditions illustrate the emerging uses of and challenges with ctDNA testing (Table 4) . 16, 19 A prospective study of 102 patients with lung cancer showed a high degree of concordance (79%) by NGS-based assay to detect clinically actionable EGFR mutations between paired tumor tissue and ctDNA, which increased to 100% as the time between tissue biopsy and blood draw decreased to within 2 weeks of each other. 7 In addition, the sensitivity of ctDNA seems to increase with the number of metastatic sites. 4 Several studies also have illustrated the predictive value of plasma EGFR positivity to targeted therapies. 1, 18, 20 In the aforementioned study of first-line gefitinib in advanced NSCLC, patients with EGFR mutation-positive ctDNA, regardless of mutation subtype, had similar response rates to those with EGFR-positive tumors (76.9% and 69.8%, respectively). 18 Recently, the US Food and Drug Administration (FDA) approved the cobas EGFR Mutation Test v2 (Roche Molecular Diagnostics, Pleasanton, CA) to detect specific NSCLC mutations (exon 19 deletion or exon 21 [L858R] substitution) in patients' blood to determine candidates for treatment with erlotinib as well as in patients with T790M mutations who would benefit from osimertinib. The positive predictive value of EGFR ctDNA testing is high enough to justify initiation of EGFR-directed therapy; however, the negative predictive value remains less robust. Therefore, a negative test result does not rule out the presence of an EGFRmutated tumor and should be confirmed with tissue-based testing.
EGFR and ALK Inhibitor Resistance Testing
Despite impressive initial responses, most patients who receive first-generation EGFR tyrosine kinase inhibitors (TKIs) will develop resistance within 10 to 16 months of treatment initiation. 7, 21 Acquired resistance to gefitinib or erlotinib in approximately 60% of patients with EGFR-mutated NSCLC develops through the emergence of EGFR T790M. 3 Identification of this genetic alteration has important clinical implications because thirdgeneration TKIs like osimertinib have demonstrated impressive and durable responses. 7 Although the gold standard for identifying T790M has been with tissue biopsy, ctDNA represents an attractive strategy in this setting because of its ability to reflect tumor heterogeneity, and the cobas EGFR Mutation Test v2 is now FDA approved to detect T790M in patients' blood. Numerous studies have used ctDNA to identify T790M mutations in NSCLC. 22 A study of 117 patients with advanced NSCLC who received Ability to capture tumor tissue heterogeneity
Limited because biopsy usually accesses one or only a few regions of the tumor.
Significant because blood sample is more representative of entirety of tumor clones.
Quality of sample Often may not be sufficient because of technical difficulty with accessing tumor.
Sufficient for testing as long as 10 mL of blood is drawn, but the yield depends on DNA shedding and tumor burden.
Testing spectrum Generally allows broader testing spectrum (ie, more genes tested as less depth of sequencing needed).
Deeper sequencing is required with ctDNA than with tumor given lower allele frequency of mutants; therefore, panels include a smaller number of genes/ mutations.
Abbreviation: ctDNA, circulating tumor DNA.
TKIs showed that the sensitivity and specificity of plasma T790M testing by ddPCR was 81.25% and 100.00%, respectively. 23 Sacher et al 4 reported a lower positive specificity (63%) for detecting EGFR T790M by plasma ddPCR, which may be attributed to tumor heterogeneity and false-negative tissue genotyping, which raises questions about the fallibility of tissue-based genotyping as the reference standard for T790M status. Another study showed that the sensitivity of plasma genotyping with BEAMing (Sysmex Inostics, Baltimore, MD) for the detection of T790M was 70%, and the objective response rate and median progression-free survival (PFS) with osimertinib were similar in patients with T790M-positive plasma or tumors. 10 This finding suggests that with the use of ctDNA testing, many patients can avoid a biopsy for T790M genotyping. However, because of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma still need to undergo tumor biopsy to determine the presence or absence of T790M. 10 In addition to cases where ctDNA is not detectable, tissue testing retains value in certain resistance mechanisms, such as small-cell transformation.
Thress et al 24 performed NGS of cfDNA from seven patients with T790M-mutated advanced lung cancer who had developed resistance to osimertinib and detected an acquired EGFR C797S mutation. They then developed a ddPCR assay to interrogate the cfDNA of 15 patients treated with osimertinib and found the EGFR C797S mutation in six patients. For patients with T790M-positive, erlotinib-resistant NSCLC who develop the C797S mutation after treatment with a thirdgeneration EGFR TKI, the specific configuration of T790M and C797S mutations affects how cells might respond to additional therapy. 25 If the two mutations are in trans (ie, on separate alleles), a combination of first-and third-generation TKIs might restore EGFR inhibition. If the two mutations are in cis (ie, on the same allele), cells will be refractory to any EGFR TKI. This trans versus cis assessment can be determined by NGS-based ctDNA assays because T790M and C797S are in proximity and can be captured on a significant number of individual sequencing reads. 26 This is not possible with PCR-based approaches because they do not provide the actual relationship on any particular strand.
Most patients who receive ALK inhibitors also will develop resistance within 1 year of therapy, and secondary ALK mutations have been identified in patients with acquired resistance. Unlike acquired T790M resistance to EGFR TKIs, one dominant secondary mutation appears not to exist, and second-generation ALK inhibitors have shown high response rates in patients previously treated with crizotinib regardless of the presence of secondary ALK mutations, which makes the role of a repeat biopsy less clear. 27 However, emerging data suggest that specific secondary resistance ALK mutations have important therapeutic implications. Some patients develop resistance to alectinib as a result of an I1171T mutation, and ceritinib has demonstrated activity against these mutations.
28 Alectinib resistance can occur as a result of the G1202R mutation, which confers resistance to most ALK inhibitors except thirdgeneration inhibitors such as lorlatinib, 29 which emphasizes the utility of genotyping patients who develop ALK inhibitor resistance, and ongoing studies are evaluating the performance of ctDNA in detecting ALK resistance mutations. 30 
EMERGING USES ctDNA Testing in Urine and CSF
DNA derived from NSCLC tumors also can be detected with high sensitivity in urine. In a study that detected EGFR mutations by an NGS assay, the sensitivity for urine was 93% for T790M, 80% for L858R, and 83% for exon 19 deletions. A comparable sensitivity was observed in plasma, and together, urine and plasma testing identified 12 additional T790M-positive cases that were not detected by tissue testing. In nine patients monitored while receiving the third-generation EGFR inhibitor rociletinib, a rapid decrease in urine T790M levels was observed by day 21. 31 In a study of patients with T790M positivity, response was similar whether T790M status was identified by tissue, plasma (through BEAMing), or urine (through NGS). 32 These data suggest that plasma and urine EGFR analyses complement tissue biopsy specimen analysis in NSCLC.
Brain metastasis is found in up to 40% patients with NSCLC, 33 and ctDNA analysis of patients with brain tumors has revealed either the absence or very low levels of tumor DNA possibly as a result of the blood-brain barrier. 34 One study used hybridization capture-based sequencing and ddPCR to characterize ctDNA in CSF of patients with brain lesions (including brain metastasis from lung cancer) and compared it with plasma ctDNA. 35 The authors concluded that CSF ctDNA has a significantly higher sensitivity than plasma for CNS genomic alterations like EGFR, PTEN, ESR1, IDH1, ERBB2, and FGFR2 and can be used to detect brain tumor mutations and monitor brain tumor progression (sensitivity of ctDNA was 58% v 0% in CSF and plasma, respectively, in CNS-restricted disease). Sasaki et al 36 analyzed seven patients with EGFR-mutated NSCLC who had developed leptomeningeal disease during gefitinib therapy. In all, the EGFR mutation detected through real-time PCR in CSF was the same as that detected in the primary tumor (sensitivity, 100%), whereas cytology was positive in only two patients (sensitivity, 28.6%). Hata et al 37 investigated the response to osimertinib in 10 patients with leptomeningeal disease and showed that the drug might be more effective in CSF of patients with T790M positivity than in those without CSF T790M positivity.
Multigene Testing
As the number of genomic targets with matched therapies grows, the National Comprehensive Cancer Network guidelines for NSCLC recommend expanded genomic testing, including for EGFR, ALK, ERBB2, BRAF, MET, ROS1, and RET. 5, 15, 38 Testing for all these alterations in addition to histopathologic and immune biomarker assessment pose a challenge when tissue biopsy samples are insufficient. In a study of patients with advanced NSCLC, a tissue biopsy specimen with sufficient quality and quantity of DNA for NGS was unobtainable for 52 (51%) of 102 patients. 7 Two studies used NGS-based ctDNA assays to evaluate, with high overall accuracy,somatic genomic profiles in patients with advanced NSCLC . Mack et al 39 identified actionable mutations in 42% of 978 patients. Zill et al 40 determined ctDNA profiles of . 15,000 patients with advanced-stage cancer with a concordance of 87% with matched tumor samples that increased to 98% when plasma and tissue testing was done , 6 months apart. The study detected actionable mutations in biopsy specimens with insufficient tissue (ALK fusion, EGFR or BRAF activating mutations) and with actionable resistance mutations at the time of progression (MET amplification or EGFR T790M) as well as in undergenotyped tumors (BRAF V600E, or ERBB2 indel).
Identification of nontargetable oncogenic drivers, such as KRAS mutations, that preclude the presence of other targetable alterations also guides clinicians to rapidly initiate alternative therapies, such as chemotherapy or immunotherapy. 5 The detection of variants in other genes may lead to the off-label use of FDA-approved therapies or enrollment in clinical trials of new therapeutic agents. 7 Several combinations of targeted therapies are based on resistance mechanisms and are being evaluated in lung cancer (eg, MEK and PI3K inhibitors in combination with EGFR TKIs), 41 which again underscores the need for real-time tumor genotyping to assess for resistance pathways. A retrospective study examined the impact of TP53 mutations identified in tissue on response to first-line TKIs in 123 patients with EGFR-mutated NSCLC. 42 The disease control rate was 70% in patients with TP53 mutations compared with 88% in those with TP53 wild type. A shorter median PFS and overall survival (OS) in patients with TP53 exon 8 mutations was observed in those with EGFR exon 19 deletion (PFS, 4.2 v 16.8 months; OS, 7.6 months v not reached, respectively). This information could be exploited to risk stratify patients who require more-aggressive therapy. Chabon et al 43 identified several resistance mechanisms, including MET, EGFR, PIK3CA, ERRB2, KRAS, and RB1, in patients with T790M-mutated NSCLC who received rociletinib. The study used cancer personalized profiling by deep sequencing ctDNA analysis and found that 46% of patients (19 of 41) with T790M mutations had additional potential resistance mutations in the pretreatment plasma. This coexistence of different resistance mechanisms in the same patient may affect response to subsequent EGFR TKIs like rociletinib.
Treatment Monitoring
ctDNA offers the possibility of serial testing for molecular monitoring of disease. The short halflife of ctDNA (2 hours) allows for the evaluation of changes in tumor burden in hours rather than in weeks to months, as done traditionally with imaging.
Studies have demonstrated the predictive value of quantitative changes in EGFR mutations in ctDNA at various time points during TKI treatment. 1 A prospective analysis to validate ddPCR for the detection of common EGFR and KRAS mutations in patients with advanced NSCLC demonstrated that patients with complete resolution of ctDNA at either 2 or 6 weeks after treatment exhibited a treatment discontinuation rate of 0% at the initial and 4% at the second imaging assessment. Patients without complete resolution exhibited a treatment discontinuation rate of 33% at initial and 56% at second imaging. These patterns were postulated to correlate with radiographic response and emergence of acquired resistance. 4 Marchetti et al 44 performed PCR and ultradeep NGS on serial plasma samples from 20 patients with advanced NSCLC and known tissue and plasma EGFR mutations before TKI treatment. Rapid responders who had at least a 50% decrease in plasma EGFR copy number at 14 days had a greater mean percentage of tumor shrinkage than slow responders (n = 6; 70% v 30%). Tseng et al 45 prospectively evaluated matched serum and tissue samples from 62 patients with advanced-stage EGFR-positive tumors treated with gefitinib. By evaluating ctDNA with peptide nucleic acid-zip nucleic acid PCR clamp method at 10 weeks and on progression of disease, the study demonstrated that the failure to clear plasma EGFR mutations was an independent predictor of a lower disease control rate (odds ratio, 5.26), shorter PFS (hazard ratio [HR], 1.97), and decreased OS (HR, 1.82). A phase III study evaluated EGFR mutations in cfDNA of patients randomly assigned to receive gemcitabine and platinum plus sequential erlotinib or placebo by using a cobas test. 46 For patients treated in the erlotinib arm who were cfDNA EGFR positive at baseline, the disappearance of cfDNA at cycle 3 was associated with significantly improved PFS (HR, 0.38) and longer OS (HR, 0.45) compared with patients with persistence of cfDNA EGFR.
The prognostic value of dynamic changes in ctDNA has also been evaluated. In the EURTAC (Erlotinib Versus Standard Chemotherapy as First-Line Treatment of European Patients With Advanced EGFR-Mutated Non-Small-Cell Lung Cancer) study, a prespecified analysis of 76 patients with cfDNA EGFR mutations by TaqMan assay revealed a shorter median OS in patients with L858R mutation than those with exon 19 deletion (13.7 v 30 months). 47 Among the 41 patients with L858R mutation in tissue, those in whom the mutation was also detected in cfDNA had a notably shorter median survival than those who did not (13.7 v 27.7 months; HR, 2.22), suggesting a prognostic value of plasma cfDNA L858R mutations.
These studies highlight the potential of real-time monitoring of tumor mutations during treatment as an early predictor of response or resistance to therapy that could inform timely treatment decisions. Additional studies are needed to evaluate end points such as PFS, OS, and quality of life as a result of early detection of resistance.
Monitoring for Minimal Residual Disease
Another potential application of ctDNA is to evaluate for minimal residual disease (MRD) after curativeintent therapy, such as surgery and radiation. 8 Chaudhuri et al 48 applied cancer personalized profiling by deep sequencing to detect ctDNA in pre-and post-treatment blood samples from 41 patients with nonmetastatic lung cancer treated with chemoradiation, radiation, or surgery. Pretreatment ctDNA was detected in 38 patients (93%), and 19 patients (46%) had detectable post-treatment ctDNA. These patients positive for MRD had a significantly worse outcome than patients without detectable ctDNA MRD within 4 months of definitive treatment (3-year freedom from progression, 0% v 92% [HR, 38]; 3-year OS, 8% v 75% [HR, 12] ). These data suggest that patients with residual ctDNA after definitive treatment will be enriched for those who will ultimately develop recurrence. ctDNA detection might facilitate the development of clinical trials that evaluate the escalation of therapy for patients at high risk for recurrence and the de-escalation of therapy for patients without residual disease.
Role in Early Diagnosis/Screening
The role of ctDNA in early-stage disease also is being studied. Bettegowda et al 34 evaluated the ability of ctDNA to detect tumors in patients with various malignancies at various clinical stages. Forty-seven percent of patients with stage I cancers (n = 49) had detectable ctDNA, with the fraction of patients with detectable ctDNA being 55%, 69%, and 82% for those with stage II, III, and IV cancers, respectively. 34 Trials are under way to assess the feasibility and utility of NGSbased ctDNA to detect early-stage cancers in high-risk patients (ClinicalTrials.gov identifier: NCT02612350; also project LUNAR 48a ). In addition to a lower rate of ctDNA detection for early-stage cancers, other challenges remain. Although this approach allows us to identify patients with early-stage disease and detectable ctDNA, by itself, it cannot be applied to screening because the mutation of interest in the patient's tumor needs to be known to send for appropriate genomic panels. ctDNA may be detectable before radiographically detectable disease, which raises the issue of managing such patients. Nevertheless, early cancer detection remains a promising new avenue for ctDNA that needs additional research.
ctDNA in the Era of Immune Checkpoint Therapy
In the era of immune therapy for advanced NSCLC, a key issue is the elucidation of a biomarker that can predict response and monitor disease. Because imaging may be less reliable as a result of possible pseudoprogression, ctDNA testing has great potential to assess disease response. Tumor DNA sequencing has been shown to be a surrogate for total mutation burden, which predicts response and PFS with anti-programmed death 1 inhibitors like pembrolizumab. 49 However, total mutation burden analysis has been investigated only in tumor tissue, and a better understanding of ctDNA is required before it can be applied for this purpose.
Lipson et al 50 analyzed the ctDNA of 12 patients with metastatic melanoma who underwent treatment with checkpoint inhibitors for the presence of hotspot somatic mutations in BRAF, cKIT, NRAS, and TERT by using BEAMing. Serial levels of ctDNA were compared with radiologic and clinical outcomes, and relevant mutations were detected in five of 10 patients. In three patients, increasing ctDNA levels correlated with radiographically progressive disease. In another patient, ctDNA levels increased initially as lymphadenopathy progressed but then became undetectable 3 weeks before clinical improvement, which suggests that changes in ctDNA are predictive of the antitumor activity of immune checkpoint inhibitors.
ISSUES IN CLINICAL PRACTICE The Meaning of a Negative Test Result
Although current ctDNA detection platforms have high analytic sensitivity and can detect extremely low levels of mutated DNA fragments, their clinical sensitivity is limited by biology because not all tumors release DNA into the circulation. Hence, a negative result could signify that the tumor is not actively shedding ctDNA, the patient's disease is adequately controlled by therapy, or somatic variants either were not covered or were below the detection limit for the assay. 7 In addition, any negative test result will need to be viewed in the overall context of ctDNA and other molecular results. For example, in a patient with an EGFR-mutated NSCLC in the setting of acquired resistance, a negative EGFR T790M test result is more likely to be a true negative if the original EGFR mutation was detected with a significant allele frequency versus if the ctDNA test did not identify either mutation.
Confidence in a Positive Test Result
Extremely high analytic specificity and a positive predictive value that approaches 100% make false positives unlikely, so if a mutation is detected, it can be relied on as a true result. As expected, the allelic fraction of variants detected in ctDNA is usually much smaller than that in tissue DNA given that tumor-derived DNA may be more diluted in the blood than in the tissue. 7 The rare false positive result (particularly T790M) in plasma may be indicative of tissue heterogeneity in which the mutation was not identified but is present in tissue, which may be due to the timing of the biopsy and the location of the biopsy needle in the tumor. The only definitive method to clinically validate that the mutations detected in plasma are an accurate molecular proxy of disease biology in the context of it being absent in tissue is to correlate them with response to targeted inhibition.
In the case of mutational events that are exclusive to certain types of cancers (eg, EGFR exon 19 deletion to NSCLC), confidence of a positive result is higher than in genes that can be mutated in a variety of settings (eg, TP53). For instance, a small allelic fraction TP53 mutation in ctDNA can originate from many sources (eg, myelodysplastic syndrome), and in such cases, confidence is increased if the same mutation also has been detected in tumor.
Detection of Concurrent Malignancy/ Germline Alterations
The testing of cfDNA will detect all DNA that sheds into the circulation, and some findings may not be expected in the tumor of origin, may not match tumor tissue DNA results, and may affect genes that are mutated in different tumor types (eg, TP53). A potential for detection of incidental hematologic malignancies exists, which, naturally, have high tumor burden in the blood, and results can be confounded by foreign DNA, such as after transfusion or organ transplantation.
Another issue similar to what is seen with tissue genotyping is that one needs to be cautious about distinguishing somatic (tumor) versus germline alterations because germline DNA is not analyzed in parallel. ctDNA may be less susceptible to this problem than tissue genotyping because somatic mutations would be expected to occur in lower allelic fractions than germline mutations. However, one still must be vigilant when interpreting reports because testing laboratories may not necessarily highlight these issues. Any mutation that affects genes implicated in familial syndromes should be considered specifically (eg, BRCA), and mutations with high allele frequency (between 30% and 70%) should raise the possibility of being potentially associated with heterozygous germline mutation syndromes.
In conclusion, tissue biopsy remains essential at least for primary diagnosis because tissue yields information about morphology, tumor type, site of origin, and the immune microenvironment. The actionability of a given gene mutation is related to cancer subtype, and thorough histopathologic diagnosis of the primary tumor is critical. For instance, ERBB2 (HER2) copy number amplification in NSCLC does not predict TKI response like it does in breast cancer. 5 Currently best validated in EGFR-mutated lung cancer for primary molecular diagnosis and for EGFR T790M testing, ctDNA has proven to have excellent utility as a complement to tissue-based testing. Multigene panel testing in plasma has shown immense promise in the setting of primary diagnosis, response monitoring, detection of MRD, and early diagnosis. Vigilance is required in the interpretation of test results, and additional studies likely will firmly establish its role in daily clinical practice.
